The FDA has given Ocugen orphan drug status for a gene therapy designed to treat NR2E3 mutation-associated retinal degenerative disease.
The Malvern, Penn.-based company’s OCU400 product includes an adeno-associated virum serotype 5 capsid that contains the gene for human nuclear hormone receptor NR2E3.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocugen wins orphan drug status for ocular gene therapy appeared first on MassDevice.